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STL	polyomavirus	(STLPyV)	was	recently	identified	in	
human	specimens.	To	determine	seropositivity	for	STLPyV,	
we	 developed	 an	 ELISA	 and	 screened	 patient	 samples	




Polyomaviruses are nonenveloped double-stranded cir-cular DNA viruses that infect a wide range of hosts, 
including humans. The capsid of the virus comprises pri-
marily 72 pentamers of the major coat protein, VP1. Hu-
man polyomaviruses have been associated with several 
diseases (1). BK polyomavirus (BKPyV) has been associ-
ated with nephropathy in renal transplant recipients and 
JC polyomavirus (JCPyV) with progressive multifocal 
leukoencephalopathy in immunocompromised persons 
(2,3). Trichodysplasia spinulosa–associated polyomavi-
rus (TSPyV) infection is linked to a rare skin disease in 
immunocompromised patients called trichodysplasia spi-
nulosa (4). Furthermore, infection with Merkel cell poly-
omavirus (MCPyV) in rare instances leads to Merkel cell 
carcinomas, an aggressive form of skin cancer (5). Other 
polyomaviruses, including WU polyomavirus (WUPyV), 
KI polyomavirus (KIPyV), human polyomavirus 6, hu-
man polyomavirus 7, human polyomavirus 9, MW poly-
omavirus (MWPyV), STL polyomavirus (STLPyV), and 
human polyomavirus 12, have been identified in speci-
mens from humans, but their role in disease remains to 
be defined (1).
Seroepidemiology has played an important role in 
establishing the link between human polyomaviruses and 
disease and in understanding infection dynamics. The se-
roprevalences of BKPyV and JCPyV range from 70% to 
90% and 40% to 60%, respectively, with an age profile in-
dicating high frequency of early-age infections and lifelong 
persistence (6–8). Seropositivity for MCPyV in healthy 
persons ranges from 25% to 64%; all patients with Merkel 
cell carcinoma are seropositive (6,9).
STLPyV was recently identified from fecal specimens 
from a child in Malawi (10). Viral DNA also was detected 
in fecal specimens from the United States and The Gam-
bia, and STLPyV has been found in a surface-sanitized 
skin wart surgically removed from the buttocks of a patient 
with a primary immunodeficiency called WHIM (warts, 
hypogammaglobulinemia, infections, and myelokathexis) 
syndrome (11). These observations suggest that STLPyV 
might infect humans. We defined the seropositivity rate of 
STLPyV in humans using serum from 2 independent US 
sites (Denver, Colorado, and St. Louis, Missouri).
The Study
To determine the seropositivity for STLPyV, we de-
veloped a capture ELISA using recombinant glutathione 
S-transferase–tagged STLPyV VP1 capsomeres (on-
line Technical Appendix, http://wwwnc.cdc.gov/EID/
article/20/9/14-0561-Techapp1.pdf). Electron microscopy 
of the STLPyV capsomeres showed 10-nm pentamers 
characteristic of polyomaviruses (Figure 1, panel A). We 
assessed the specificity of the STLPyV ELISA by pre-
incubating 24 serum samples in the presence and absence 
of soluble STLPyV VP1 pentamers before addition to the 
immobilized STLPyV glutathione S-transferase–tagged 
VP1. The ELISA signal intensity was markedly reduced 
when serum was pre-incubated with STLPyV VP1 pentam-
ers (Figure 1, panel B; compare white bars to gray bars). 
This result indicates the ELISA seroreactivity could be 
self-competed with soluble STLPyV pentamers. STLPyV 
shares 55% aa identity in the VP1 region with its next most 
closely related polyomavirus, MWPyV (10). Therefore, we 
examined whether cross-reactivity existed between STL-
PyV and MWPyV VP1 capsomeres. Competition assays 
with soluble MWPyV VP1 pentamers showed limited inter-
ference with the ELISA seroreactivity (Figure 1, panel C; 
compare white bars to gray bars). This result indicates that 
there was no significant cross-reactivity between STLPyV 
and MWPyV VP1 capsomeres. Taken together, these data 
demonstrate that the ELISA was specific to STLPyV VP1.
We screened 500 serum specimens collected from 
children and adults in Denver for antibodies against STL-
PyV. The overall seropositivity for STLPyV was 68.0% 
(Figure 2, panel A). Children 1–3 years of age had the low-
est seropositivity rate (23.8%). In contrast, seroprevalence 
of children 4–20 years of age ranged from 61.1% to 70.8%. 
Similar seropositivity rates persisted in adults (>21 years of 
age), ranging from 68.8% to 74.2%.
We next examined a panel of 419 serum specimens 
from St. Louis that had a higher resolution of age-strati-
fication in young infants. The overall seropositivity for 
STLPyV was 70.0% (Figure 2, panel B), similar to that 
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in the specimens from Denver (68.0%). Seropositivity for 
STLPyV in infants dropped from 53.3% in the <0.5-year 
age group to 37.9% in the 0.5–1-year age group, with the 
lowest seropositivity of 22.6% in the 1–2-year group. In 
contrast, seropositivity rates for children >2 years of age 
were higher, ranging from 60.0% to 85.3%. Finally, sero-
positivity in adults (>21 years of age) ranged from 91.2% to 
95.2%. Thus, these data indicate that exposure to STLPyV 
occurs during early childhood and that immune responses 
to STLPyV are maintained in adults.
Conclusions
In our analysis of the seroepidemiology of STLPyV 
in 2 areas of the United States, we found that prevalence 
of the virus was similar (68.0%–70.0%). This prevalence 
is slightly higher than the 41.8% for MWPyV, the poly-
omavirus most closely related to STLPyV (12). However, 
the seropositivity of STLPyV is comparable to other hu-
man polyomaviruses (>60%), such as BKPyV, KIPyV, 
WUPyV, MCPyV, human polyomavirus 6, and TSPyV 
(6,8). We found no cross-reactivity with MWPyV VP1, the 
most closely-related polyomavirus that shares 55% aa iden-
tity in the VP1 region. Thus, the seroepidemiology strongly 
supports the notion that STLPyV is a bona fide infectious 
agent of humans.
Age stratification of the seropositive specimens sug-
gested an initial waning of immune response followed by 
rapid seroconversion during childhood. In the St. Louis 
specimens, seropositivity was higher for the <0.5-year and 
0.5–1-year age groups (53.3% and 37.9%, respectively) 
than for the 1–2-year group (22.6%). This observation was 
followed by an increase in STLPyV seropositivity in the 
2–3-year group and older age groups (60.0%). Specimens 
from Denver were too few to reliably stratify the data to 
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the same resolution. Nonetheless, we observed a similar 
trend in specimens from Denver where the seropositivity 
for the 1–3-year age group (23.8%) was lower than for the 
4–6-year group (61.1%). These data indicate that immune 
responses to STLPyV decreased in the first 2 years of age, 
which suggests waning maternal antibodies. However, 
seropositivity was rapidly acquired thereafter, indicating 
high exposure of STLPyV in children. Because the speci-
mens were selected from hospital-associated blood draws 
of children of unknown health status, seropositivity rates 
for healthy children might have varied somewhat from the 
results we obtained. Nonetheless, the trends we observed 
with STLPyV are similar to profiles that have been reported 
for JCPyV, BKPyV, TSPyV, MCPyV, WUPyV, and KIP-
yV (6,13–15).
STLPyV has not been clearly associated with any 
disease. However, the high overall seropositivity rate 
suggests widespread infection in the population at large. 
None of the pathogenic human polyomaviruses (JCPyV, 
BKPyV, MCPyV, TSPyV) have been clearly associated 
with acute disease at the time of initial infection. Rather, 
immunosuppression is a critical co-factor that is coupled 
to the ability of polyomaviruses to persist throughout 
life or to integrate into the genome, as in the case of 
MCPyV, ultimately leading to disease. Our study dem-
onstrates that a large segment of the general population 
has been infected by STLPyV and might harbor persistent 
STLPyV infection, assuming the persistence paradigms 
of JCPyV and BKPyV hold true for STLPyV. A recent 
report identified STLPyV DNA in a skin wart specimen 
from an adult with primary immunodeficiency (11). Thus, 
it is critical to determine whether human diseases exist 
that are caused by STLPyV, especially in immunocom-
promised persons.
R.L.G. was supported by National Institutes of Health grant 
CA37667. D.W. holds an investigator in the pathogenesis of 
infectious disease award from the Burroughs Wellcome Fund. 
E.S.L. is an Eli and Edythe Broad Fellow of the Life Sciences 
Research Foundation.
Dr Lim is a postdoctoral research associate at Washington 
University in St. Louis. His research focuses on the discovery and 
characterization of novel viruses and human pathogens.
References
  1. DeCaprio JA, Garcea RL. A cornucopia of human polyomaviruses. 
Nat Rev Microbiol. 2013;11:264–76. http://dx.doi.org/10.1038/ 
nrmicro2992
  2. Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, 
Khalili K, et al. Molecular biology, epidemiology, and pathogenesis 
of progressive multifocal leukoencephalopathy, the JC virus- 
induced demyelinating disease of the human brain. Clin Microbiol 
Rev. 2012;25:471–506. http://dx.doi.org/10.1128/CMR.05031-11
  3. Kuypers DR. Management of polyomavirus-associated nephropathy 
in renal transplant recipients. Nat Rev Nephrol. 2012;8:390–402. 
http://dx.doi.org/10.1038/nrneph.2012.64
  4. van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, 
Gorbalenya AE, Feltkamp MC. Discovery of a new human poly-
omavirus associated with trichodysplasia spinulosa in an immu-
nocompromized patient. PLoS Pathog. 2010;6:e1001024. http://
dx.doi.org/10.1371/journal.ppat.1001024
  5. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a poly-
omavirus in human Merkel cell carcinoma. Science. 2008;319:1096–
100. http://dx.doi.org/10.1126/science.1152586
  6. Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human 
polyomaviruses. PLoS Pathog. 2009;5:e1000363. http://dx.doi.org/ 
10.1371/journal.ppat.1000363
  7. Viscidi RP, Rollison DE, Sondak VK, Silver B, Messina JL, 
Giuliano AR, et al. Age-specific seroprevalence of Merkel cell 
polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol. 
2011;18:1737–43. http://dx.doi.org/10.1128/CVI.05175-11
  8. Moens U, Van Ghelue M, Song XB, Ehlers B. Serological cross-
reactivity between human polyomaviruses. Rev Med Virol. 
2013;23:250–64. http://dx.doi.org/10.1002/rmv.1747
  9. Tolstov YL, Pastrana DV, Feng HC, Becker JC, Jenkins FJ, 
Moschos S, et al. Human Merkel cell polyomavirus infec-
tion II. MCV is a common human infection that can be detected 
by conformational capsid epitope immunoassays. Int J Cancer. 
2009;125:1250–6. http://dx.doi.org/10.1002/ijc.24509
10. Lim ES, Reyes A, Antonio M, Saha D, Ikumapayi UN, Adeyemi M, 
et al. Discovery of STL polyomavirus, a polyomavirus of ancestral 
recombinant origin that encodes a unique T antigen by alternative 
splicing. Virology. 2013;436:295–303. http://dx.doi.org/10.1016/ 
j.virol.2012.12.005
11. Pastrana DV, Fitzgerald PC, Phan GQ, Raiji MT, Murphy PM, 
McDermott DH, et al. A divergent variant of the eleventh human 
polyomavirus species, St. louis polyomavirus. Genome Announc. 
2013;1:e00812–3. http://dx.doi.org/10.1128/genomeA.00812-13
12. Nicol JT, Leblond V, Arnold F, Guerra G, Mazzoni E, Tognon M, 
et al. Seroprevalence of human Malawi polyomavirus. J Clin Micro-
biol. 2014;52:321–3. http://dx.doi.org/10.1128/JCM.02730-13
13. Nguyen NL, Le BM, Wang D. Serologic evidence of frequent 
human infection with WU and KI polyomaviruses. Emerg Infect 
Dis. 2009;15:1199–205. http://dx.doi.org/10.3201/eid1508.090270
14. Martel-Jantin C, Pedergnana V, Nicol JT, Leblond V, Trégouët DA, 
Tortevoye P, et al. Merkel cell polyomavirus infection occurs during 
early childhood and is transmitted between siblings. J Clin Virol. 
2013;58:288–91. http://dx.doi.org/10.1016/j.jcv.2013.06.004
15. van der Meijden E, Bialasiewicz S, Rockett RJ, Tozer SJ, 
Sloots TP, Feltkamp MC. Different serologic behavior of MCPyV, 
TSPyV, HPyV6, HPyV7 and HPyV9 polyomaviruses found on the 
skin. PLoS ONE. 2013;8:e81078. http://dx.doi.org/10.1371/journal.
pone.0081078
Address for correspondence: Robert L. Garcea, University of Colorado, 
School of Medicine, Molecular, Cellular, & Developmental Biology, 
and The BioFrontiers Institute, Jennie Smoly Caruthers Biotechnology 







Manage your email alerts so you only  
receive content of interest to you.
Sign up for an online subscription:
http://wwwnc.cdc.gov/eid/subscribe.htm
